ABIONYX PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.074 EUR | -1.83% |
|
-3.24% | -16.61% |
| Mar. 14 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
| Mar. 11 | Abionyx: reduced net loss in 2023 | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases.
At the end of 2022, the company boasted a portfolio of 3 products in clinical development.
Calendar
2024-05-15
- Q1 2024 Sales and Revenue Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.074
EUR
Average target price
10.5
EUR
Spread / Average Target
+877.65%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.61% | 37.49M | |
| -3.30% | 102B | |
| +1.79% | 96.84B | |
| -0.44% | 21.48B | |
| -18.35% | 20.82B | |
| -7.45% | 18.6B | |
| -40.31% | 16.81B | |
| -26.84% | 13.78B | |
| +0.59% | 13.4B | |
| +20.86% | 11.06B |
- Stock Market
- Equities
- ABNX Stock
- News ABIONYX Pharma
- Abionyx Pharma Names IRIS Pharma Founder as Chief Scientific Officer Amid Purchase Agreement
